AbbVie Inc. 8-KCurrent Reports (8-K / ad hoc)

Period 2026-08-18 · filed 2026-08-18

Source document

Loading document…
Sections2

Loading sections…

Sections in this filing

Financial Statements

Item 8.01. Other Events. On August 18, 2026, AbbVie Inc. (“ AbbVie ”) completed its previously announced underwritten public offering (the “ Notes Offering ”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “ Floating Rate Notes ”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due 2028 (the “ 2028 Notes ”), $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2030 (the “ 2030 Notes ”), $1,500,000,000 aggregate principal amount of its 4.875% senior notes due 2031 (the “ 2031 Notes ”), $1,250,000,000 aggregate principal amount of its 5.050% senior notes due 2033 (the “ 2033 Notes ”), $1,500,000,000 aggregate principal amount of its 5.300% senior notes due 2036 (the “ 2036 Notes ”), $1,000,000,000 aggregate principal amount of its 5.450% senior notes due 2038 (the “ 2038 Notes ”), $1,500,000,000 aggregate principal amount of its 6.000% senior notes due 2056 (the “ 2056 Notes ”) and $500,000,000 aggregate principal amount of its 6.100% senior notes due 2066 (the “ 2066 Notes ” and, together with the 2028 Notes, the 2030 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes, the 2038 Notes and the 2056 Notes, the “Fixed Rate Notes” and, collectively with the Floating Rate Notes, the “ Notes ”). The offering of each series of Notes was registered under the Securities Act of 1933, as amended (the “ Act ”), pursuant to AbbVie’s registration statement on Form S-3ASR (File No. 333-284980) (the “ Registration Statement ”) dated as of February 14, 2025. The terms of the Notes are further described in AbbVie’s prospectus supplement dated August 4, 2026, as filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) of the Act on August 6, 2026. The Notes are governed by the Indenture, dated November 8, 2012 (the “ Base Indenture ”), between AbbVie and U.S. Bank Trust Company, National Association, as successor-in-interest to U.S. Bank National Association, as trustee (the “ Trustee ”), as supplemented by that certain Supplemental Indenture No. 13, dated as of August 18, 2026, with respect to the Notes (the “ Supplemental Indenture ” and, together with the Base Indenture as so supplemented, the “ Indenture ”). The Floating Rate Notes and the 2028 Notes will mature on August 18, 2028, and the 2030 Notes will mature on March 15, 2030. All other series of Notes will mature